A detailed history of Advisor Shares Investments LLC transactions in Gh Research PLC stock. As of the latest transaction made, Advisor Shares Investments LLC holds 36,011 shares of GHRS stock, worth $420,608. This represents 0.05% of its overall portfolio holdings.

Number of Shares
36,011
Previous 31,205 15.4%
Holding current value
$420,608
Previous $208,000 21.15%
% of portfolio
0.05%
Previous 0.04%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

BUY
$6.3 - $10.95 $30,277 - $52,625
4,806 Added 15.4%
36,011 $252,000
Q3 2024

Nov 14, 2024

BUY
$6.69 - $12.49 $57,534 - $107,414
8,600 Added 38.04%
31,205 $208,000
Q2 2024

Aug 07, 2024

SELL
$10.5 - $14.81 $78,309 - $110,452
-7,458 Reduced 24.81%
22,605 $263,000
Q1 2024

May 14, 2024

SELL
$5.34 - $11.09 $97,385 - $202,248
-18,237 Reduced 37.76%
30,063 $320,000
Q4 2023

Feb 13, 2024

BUY
$5.26 - $11.04 $10,399 - $21,826
1,977 Added 4.27%
48,300 $280,000
Q3 2023

Nov 06, 2023

BUY
$9.8 - $14.15 $11,701 - $16,895
1,194 Added 2.65%
46,323 $465,000
Q2 2023

Aug 09, 2023

SELL
$7.88 - $12.74 $9,700 - $15,682
-1,231 Reduced 2.66%
45,129 $535,000
Q1 2023

May 09, 2023

BUY
$6.02 - $10.92 $102,954 - $186,753
17,102 Added 58.45%
46,360 $370,000
Q4 2022

Feb 14, 2023

SELL
$9.2 - $13.5 $7,341 - $10,773
-798 Reduced 2.66%
29,258 $284,000
Q3 2022

Nov 14, 2022

BUY
$10.15 - $16.15 $52,993 - $84,319
5,221 Added 21.02%
30,056 $349,000
Q2 2022

Aug 08, 2022

BUY
$8.99 - $19.87 $49,094 - $108,510
5,461 Added 28.19%
24,835 $248,000
Q1 2022

May 09, 2022

BUY
$15.48 - $23.98 $79,443 - $123,065
5,132 Added 36.03%
19,374 $354,000
Q4 2021

Jan 31, 2022

BUY
$14.1 - $27.9 $147,683 - $292,224
10,474 Added 277.97%
14,242 $332,000
Q3 2021

Nov 04, 2021

BUY
$16.51 - $23.68 $62,209 - $89,226
3,768 New
3,768 $83,000

Others Institutions Holding GHRS

About GH Research PLC


  • Ticker GHRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,020,800
  • Market Cap $608M
  • Description
  • GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH0...
More about GHRS
Track This Portfolio

Track Advisor Shares Investments LLC Portfolio

Follow Advisor Shares Investments LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Shares Investments LLC, based on Form 13F filings with the SEC.

News

Stay updated on Advisor Shares Investments LLC with notifications on news.